Streetbeat News

FSNUY

Fresenius SE & Co. KGaA

https://www.fresenius.de/

CEO

Stephan Sturm

Industry

Surgical and Medical Instrument Manufacturing

Open

10.82

Mkt cap

24B

Volume

2.5K

High

10.88

P/E Ratio

49.05

52-wk high

11.23

Low

10.76

Div yield

N/A

52-wk low

6.57

Fresenius SE has experienced a significant turnaround, with a 50% stock price increase and a 50.6% rise in operating income. The company's restructuring into Helios and Kabi segments has driven growth, especially in the biosimilar market. Debt reduction and dividend reinstatement highlight financial health.

Portfolio Pulse from

March 16, 2025 | 4:00 pm

Fresenius is experiencing a significant turnaround with a 25% return on investment since early 2024, driven by strong earnings growth and strategic execution. The company has improved EPS, reduced leverage, and strong performance in key segments like Kabi and Helios. A conservative price target of €35/share suggests a 60% return over the next 3 years.

Portfolio Pulse from

January 04, 2025 | 7:00 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.